Shandong Sito Bio-technology Co Ltd (300583) - Net Assets
Based on the latest financial reports, Shandong Sito Bio-technology Co Ltd (300583) has net assets worth CN¥1.80 Billion CNY (≈ $263.58 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.93 Billion ≈ $428.99 Million USD) and total liabilities (CN¥1.13 Billion ≈ $165.41 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how strategically is Shandong Sito Bio-technology Co Ltd's equity deployed to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.80 Billion |
| % of Total Assets | 61.44% |
| Annual Growth Rate | 36.17% |
| 5-Year Change | 3.73% |
| 10-Year Change | 197.95% |
| Growth Volatility | 80.2 |
Shandong Sito Bio-technology Co Ltd - Net Assets Trend (2012–2025)
This chart illustrates how Shandong Sito Bio-technology Co Ltd's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see 300583 stock market capitalisation.
Annual Net Assets for Shandong Sito Bio-technology Co Ltd (2012–2025)
The table below shows the annual net assets of Shandong Sito Bio-technology Co Ltd from 2012 to 2025. Also explore Shandong Sito Bio-technology Co Ltd annual equity growth to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥1.80 Billion ≈ $262.91 Million |
-4.64% |
| 2024-12-31 | CN¥1.88 Billion ≈ $275.71 Million |
-8.78% |
| 2023-12-31 | CN¥2.07 Billion ≈ $302.24 Million |
+16.63% |
| 2022-12-31 | CN¥1.77 Billion ≈ $259.14 Million |
+2.25% |
| 2021-12-31 | CN¥1.73 Billion ≈ $253.45 Million |
+2.40% |
| 2020-12-31 | CN¥1.69 Billion ≈ $247.50 Million |
-10.36% |
| 2019-12-31 | CN¥1.89 Billion ≈ $276.09 Million |
+1.34% |
| 2018-12-31 | CN¥1.86 Billion ≈ $272.45 Million |
+9.06% |
| 2017-12-31 | CN¥1.71 Billion ≈ $249.81 Million |
+183.11% |
| 2016-12-31 | CN¥603.01 Million ≈ $88.24 Million |
+19.02% |
| 2015-12-31 | CN¥506.66 Million ≈ $74.14 Million |
+74.23% |
| 2014-12-31 | CN¥290.80 Million ≈ $42.55 Million |
+194.24% |
| 2013-12-31 | CN¥98.83 Million ≈ $14.46 Million |
+204.38% |
| 2012-12-31 | CN¥32.47 Million ≈ $4.75 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Shandong Sito Bio-technology Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 20102740500.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥198.50 Million | 11.26% |
| Other Components | CN¥1.56 Billion | 88.74% |
| Total Equity | CN¥1.76 Billion | 100.00% |
Shandong Sito Bio-technology Co Ltd Competitors by Market Cap
The table below lists competitors of Shandong Sito Bio-technology Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Fenerbahce Futbol AS
IS:FENER
|
$362.56 Million |
|
Dipula Income Fund Ltd
JSE:DIB
|
$362.97 Million |
|
Parag Milk Foods Limited
NSE:PARAGMILK
|
$362.99 Million |
|
Shanghai Information2 Software Inc. A
SHG:688435
|
$363.02 Million |
|
AVI Japan Opportunity Trust PLC
LSE:AJOT
|
$362.51 Million |
|
Bigcommerce Holdings Inc
NASDAQ:BIGC
|
$362.50 Million |
|
Shenzhen Kexin Communication Technologies Co Ltd
SHE:300565
|
$362.47 Million |
|
Zhejiang Wanfeng Chemical Co. Ltd. A
SHG:603172
|
$362.44 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shandong Sito Bio-technology Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,839,121,540 to 1,762,180,008, a change of -76,941,532 (-4.2%).
- Net loss of 73,147,490 reduced equity.
- Dividend payments of 27,764,901 reduced retained earnings.
- Other factors increased equity by 23,970,859.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-73.15 Million | -4.15% |
| Dividends Paid | CN¥27.76 Million | -1.58% |
| Other Changes | CN¥23.97 Million | +1.36% |
| Total Change | CN¥- | -4.18% |
Book Value vs Market Value Analysis
This analysis compares Shandong Sito Bio-technology Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.41x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 5.75x to 1.41x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | CN¥2.27 | CN¥13.06 | x |
| 2015-12-31 | CN¥3.74 | CN¥13.06 | x |
| 2016-12-31 | CN¥4.51 | CN¥13.06 | x |
| 2017-12-31 | CN¥10.10 | CN¥13.06 | x |
| 2018-12-31 | CN¥10.58 | CN¥13.06 | x |
| 2019-12-31 | CN¥10.77 | CN¥13.06 | x |
| 2020-12-31 | CN¥9.59 | CN¥13.06 | x |
| 2021-12-31 | CN¥9.88 | CN¥13.06 | x |
| 2022-12-31 | CN¥9.84 | CN¥13.06 | x |
| 2023-12-31 | CN¥11.03 | CN¥13.06 | x |
| 2024-12-31 | CN¥9.74 | CN¥13.06 | x |
| 2025-12-31 | CN¥9.29 | CN¥13.06 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shandong Sito Bio-technology Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -4.15%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -7.19%
- • Asset Turnover: 0.34x
- • Equity Multiplier: 1.68x
- Recent ROE (-4.15%) is below the historical average (10.95%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -4.60% | -13.53% | 0.18x | 1.85x | CN¥-4.74 Million |
| 2013 | 42.05% | 14.66% | 1.35x | 2.13x | CN¥31.68 Million |
| 2014 | 57.00% | 31.81% | 1.03x | 1.74x | CN¥136.67 Million |
| 2015 | 39.09% | 27.99% | 0.80x | 1.75x | CN¥139.19 Million |
| 2016 | 17.45% | 17.81% | 0.61x | 1.62x | CN¥43.21 Million |
| 2017 | 5.44% | 11.71% | 0.39x | 1.20x | CN¥-77.01 Million |
| 2018 | 6.97% | 11.98% | 0.41x | 1.43x | CN¥-54.74 Million |
| 2019 | 3.02% | 5.73% | 0.32x | 1.63x | CN¥-128.00 Million |
| 2020 | -10.94% | -19.69% | 0.32x | 1.73x | CN¥-344.11 Million |
| 2021 | 2.15% | 3.01% | 0.40x | 1.76x | CN¥-132.07 Million |
| 2022 | 2.44% | 3.20% | 0.44x | 1.74x | CN¥-130.05 Million |
| 2023 | 2.27% | 3.56% | 0.39x | 1.61x | CN¥-155.61 Million |
| 2024 | -4.83% | -9.15% | 0.32x | 1.65x | CN¥-272.68 Million |
| 2025 | -4.15% | -7.19% | 0.34x | 1.68x | CN¥-249.37 Million |
Industry Comparison
This section compares Shandong Sito Bio-technology Co Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $3,630,540,352
- Average return on equity (ROE) among peers: 6.96%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shandong Sito Bio-technology Co Ltd (300583) | CN¥1.80 Billion | -4.60% | 0.63x | $362.54 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $89.81 Million | 2.75% | 1.57x | $9.88 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $56.30 Million | 0.00% | 2.39x | $1.37 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $445.86 Million | 0.46% | 0.45x | $483.41 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $712.38 Million | 3.28% | 0.06x | $575.51 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.67 Billion | 2.43% | 1.21x | $1.61 Billion |
| Hualan Biological EngineeringInc (002007) | $1.86 Billion | 32.78% | 0.08x | $3.46 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $2.09 Billion | 4.42% | 0.71x | $1.10 Billion |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $25.90 Billion | 5.00% | 0.05x | $4.76 Billion |
| Baolingbao Biology Co Ltd (002286) | $1.44 Billion | 2.86% | 0.17x | $428.14 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $2.05 Billion | 15.59% | 0.13x | $1.62 Billion |
About Shandong Sito Bio-technology Co Ltd
Shandong Sito Bio-technology Co., Ltd. researches, develops, and produces steroid biomedicine intermediates. Its products include 9a-hydroxyandrost, 17a-hydroxyprogesterone, 17a-hydroxy progesterone derivatives, anecort acetate, bis-decyl alcohol (BA), neomycin sulfate, progesterone intermediate, tylvalosin tartrate, tetraene acetate, androstenedione, bisnoralcohol, norandrostenedione, 16ß and 16… Read more